Annual Cash & Cash Equivalents:
$2.58B-$449.56M(-14.86%)Summary
- As of today, TAK annual cash & cash equivalents is $2.58 billion, with the most recent change of -$449.56 million (-14.86%) on March 31, 2025.
- During the last 3 years, TAK annual cash & cash equivalents has fallen by -$4.43 billion (-63.21%).
- TAK annual cash & cash equivalents is now -84.79% below its all-time high of $16.93 billion, reached on March 31, 2008.
Performance
TAK Cash and Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly Cash & Cash Equivalents:
$4.61B+$2.19B(+90.43%)Summary
- As of today, TAK quarterly cash & cash equivalents is $4.61 billion, with the most recent change of +$2.19 billion (+90.43%) on September 1, 2025.
- Over the past year, TAK quarterly cash & cash equivalents has dropped by -$1.39 billion (-23.16%).
- TAK quarterly cash & cash equivalents is now -56.25% below its all-time high of $10.55 billion, reached on March 31, 2011.
Performance
TAK Quarterly Cash & Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
TAK Cash and Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1Y1 Year | -14.9% | -23.2% |
| 3Y3 Years | -63.2% | -16.3% |
| 5Y5 Years | - | -22.8% |
TAK Cash and Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | |
|---|---|---|---|---|---|
| 3Y | 3-Year | -63.2% | at low | -23.2% | +125.6% |
| 5Y | 5-Year | -70.5% | at low | -47.2% | +125.6% |
| All-Time | All-Time | -84.8% | +48.6% | -56.3% | +125.6% |
TAK Cash and Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2025 | - | $4.61B(+90.4%) |
| Jun 2025 | - | $2.42B(-5.9%) |
| Mar 2025 | $2.58B(-14.9%) | $2.58B(-18.1%) |
| Dec 2024 | - | $3.14B(-47.6%) |
| Sep 2024 | - | $6.01B(+20.1%) |
| Jun 2024 | - | $5.00B(+65.3%) |
| Mar 2024 | $3.02B(-24.5%) | $3.02B(+47.9%) |
| Dec 2023 | - | $2.05B(-4.0%) |
| Sep 2023 | - | $2.13B(-2.6%) |
| Jun 2023 | - | $2.19B(-45.4%) |
| Mar 2023 | $4.01B(-42.7%) | $4.01B(-22.8%) |
| Dec 2022 | - | $5.19B(-5.8%) |
| Sep 2022 | - | $5.51B(+16.0%) |
| Jun 2022 | - | $4.76B(-32.1%) |
| Mar 2022 | $7.00B(-19.9%) | $7.00B(+11.3%) |
| Dec 2021 | - | $6.29B(+15.5%) |
| Sep 2021 | - | $5.45B(-7.7%) |
| Jun 2021 | - | $5.90B(-32.5%) |
| Mar 2021 | $8.74B(+37.9%) | $8.74B(+46.2%) |
| Dec 2020 | - | $5.98B(+0.1%) |
| Sep 2020 | - | $5.98B(+9.4%) |
| Jun 2020 | - | $5.47B(-7.4%) |
| Mar 2020 | - | $5.91B(+12.9%) |
| Dec 2019 | - | $5.23B(-5.1%) |
| Jun 2019 | - | $5.51B(-13.1%) |
| Mar 2019 | $6.34B(+79.8%) | $6.34B(+133.6%) |
| Dec 2018 | - | $2.71B(+29.9%) |
| Jun 2018 | - | $2.09B(-40.8%) |
| Mar 2018 | $3.53B(+4.5%) | $3.53B(-9.7%) |
| Dec 2017 | - | $3.91B(-10.4%) |
| Jun 2017 | - | $4.36B(+29.3%) |
| Mar 2017 | $3.38B(-32.3%) | $3.38B(-46.7%) |
| Dec 2016 | - | $6.33B(-11.4%) |
| Jun 2016 | - | $7.14B(+43.4%) |
| Mar 2016 | $4.98B | $4.98B(-9.3%) |
| Dec 2015 | - | $5.49B(-1.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2015 | - | $5.57B(+6.9%) |
| Jun 2015 | - | $5.21B(-12.4%) |
| Mar 2015 | $5.95B(-28.0%) | $5.95B(-16.7%) |
| Dec 2014 | - | $7.14B(-6.9%) |
| Sep 2014 | - | $7.67B(+4.7%) |
| Mar 2014 | $8.26B(+38.3%) | - |
| Sep 2013 | - | $7.33B(+89.1%) |
| Jun 2013 | - | $3.87B(-20.6%) |
| Mar 2013 | $5.98B(+7.9%) | - |
| Dec 2012 | - | $4.88B(-7.8%) |
| Sep 2012 | - | $5.30B(+10.8%) |
| Jun 2012 | - | $4.78B(-54.7%) |
| Mar 2012 | $5.54B(-47.5%) | - |
| Mar 2011 | $10.55B(+11.6%) | $10.55B(+12.2%) |
| Dec 2010 | - | $9.40B(+7.9%) |
| Jun 2010 | - | $8.71B(+0.5%) |
| Mar 2010 | $9.45B(+23.0%) | - |
| Dec 2009 | - | $8.67B(-3.9%) |
| Sep 2009 | - | $9.03B(+289.4%) |
| Mar 2009 | $7.68B(-54.6%) | $2.32B(-5.5%) |
| Dec 2008 | - | $2.45B |
| Mar 2008 | $16.93B(+11.1%) | - |
| Mar 2007 | $15.24B(-3.1%) | - |
| Mar 2006 | $15.73B(+10.6%) | - |
| Mar 2005 | $14.23B(+11.9%) | - |
| Mar 2004 | $12.71B(+29.3%) | - |
| Mar 2003 | $9.84B(+38.5%) | - |
| Mar 2002 | $7.10B(+23.0%) | - |
| Mar 2001 | $5.77B(-7.3%) | - |
| Mar 2000 | $6.23B(+76.7%) | - |
| Mar 1997 | $3.52B(-3.8%) | - |
| Mar 1996 | $3.66B(-10.1%) | - |
| Mar 1995 | $4.07B(+22.4%) | - |
| Mar 1994 | $3.32B(+29.2%) | - |
| Mar 1993 | $2.57B(+23.7%) | - |
| Mar 1992 | $2.08B(+20.0%) | - |
| Mar 1991 | $1.73B | - |
FAQ
- What is Takeda Pharmaceutical Company Limited annual cash & cash equivalents?
- What is the all-time high annual cash & cash equivalents for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited annual cash & cash equivalents year-on-year change?
- What is Takeda Pharmaceutical Company Limited quarterly cash & cash equivalents?
- What is the all-time high quarterly cash & cash equivalents for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited quarterly cash & cash equivalents year-on-year change?
What is Takeda Pharmaceutical Company Limited annual cash & cash equivalents?
The current annual cash & cash equivalents of TAK is $2.58B
What is the all-time high annual cash & cash equivalents for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high annual cash & cash equivalents is $16.93B
What is Takeda Pharmaceutical Company Limited annual cash & cash equivalents year-on-year change?
Over the past year, TAK annual cash & cash equivalents has changed by -$449.56M (-14.86%)
What is Takeda Pharmaceutical Company Limited quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of TAK is $4.61B
What is the all-time high quarterly cash & cash equivalents for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high quarterly cash & cash equivalents is $10.55B
What is Takeda Pharmaceutical Company Limited quarterly cash & cash equivalents year-on-year change?
Over the past year, TAK quarterly cash & cash equivalents has changed by -$1.39B (-23.16%)